As an oral multitarget tyrosine kinase inhibitor, regorafenib inhibits angiogenesis and other tumor-driven pathways, such as vascular endothelial growth factor receptor (VEGFR) 1-3, PDGFR, fibroblast growth factor receptor (FGFR), the angiopoietin receptor TIE-2, tyrosine kinase receptors, receptor tyrosine kinase genes, leukemia factor 1, the BRAF gene and other protein kinase activities (36, 37). This evidence concerns the gene NTRK1 and neoplasm.